

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
20 September 2018 (20.09.2018)



(10) International Publication Number
WO 2018/168818 A1

(51) International Patent Classification:

C07D 215/48 (2006.01) *A61P 37/00* (2006.01)
A61K 31/47 (2006.01) *A61P 43/00* (2006.01)
A61K 31/4709 (2006.01) *C07D 215/20* (2006.01)
A61K 31/4747 (2006.01) *C07D 221/04* (2006.01)
A61K 31/5375 (2006.01) *C07D 401/06* (2006.01)
A61K 31/5386 (2006.01) *C07D 401/12* (2006.01)
A61P 9/06 (2006.01) *C07D 405/12* (2006.01)
A61P 13/12 (2006.01) *C07D 417/12* (2006.01)
A61P 19/00 (2006.01) *C07D 491/08* (2006.01)
A61P 25/00 (2006.01) *C07D 498/10* (2006.01)
A61P 29/00 (2006.01) *C07F 7/18* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/JP2018/009627

(22) International Filing Date:

13 March 2018 (13.03.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2017-047794 13 March 2017 (13.03.2017) JP

(71) Applicants: **RAQUALIA PHARMA INC.** [JP/JP];
1-21-19 Meieki Minami, Nakamura-ku, Nagoya-shi, Aichi,
4500003 (JP). **ASAHI KASEI PHARMA CORPO-**
RATION [JP/JP]; 1-1-2 Yurakucho, Chiyoda-ku, Tokyo,
1000006 (JP).

(72) Inventors: **NOGUCHI, Hirohide**; c/o RaQualia Phar-
ma Inc., 1-21-19 Meieki Minami, Nakamura-ku, Nagoya-
shi, Aichi, 4500003 (JP). **ARANO, Yoshimasa**; c/o
RaQualia Pharma Inc., 1-21-19 Meieki Minami, Nakamu-
ra-ku, Nagoya-shi, Aichi, 4500003 (JP). **ANDO, Kazuo**;
c/o RaQualia Pharma Inc., 1-21-19 Meieki Minami, Naka-
mura-ku, Nagoya-shi, Aichi, 4500003 (JP). **TOYOSHI-**
MA, Kazuki; c/o Asahi Kasei Pharma Corporation,
1-105, Kanda Jinbocho, Chiyoda-ku, Tokyo, 1018101 (JP).
SONE, Toshihiko; c/o Asahi Kasei Pharma Corporation,
1-105, Kanda Jinbocho, Chiyoda-ku, Tokyo, 1018101 (JP).
MATSUBARA, Koki; c/o Asahi Kasei Pharma Corpora-
tion, 1-105, Kanda Jinbocho, Chiyoda-ku, Tokyo, 1018101
(JP).

(74) Agent: **IWATANI, Ryo**; KEIHAN Dojima Bldg. 6F, 1-31,
Dojima 2-chome, Kita-ku, Osaka-shi, Osaka, 5300003 (JP).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

WO 2018/168818 A1

(54) Title: TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS

(57) Abstract: The present invention relates to tetrahydroquinoline derivatives of the present invention or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the P2X7 receptor.